Manzo Pharmaceuticals Inc. (MNZO)
Market Closed
10 Aug, 20:00
EXPM EXPM Primary $
0. 00
0
0%
$
115.95K Market Cap
0 P/E Ratio
- Div Yield
2.48M Volume
0 Eps
$ 0
Previous Close Want to track MNZO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
MNZO closed Monday higher at $0, an increase of 0% from Friday's close, completing a monthly increase of 0% or $0. Over the past 12 months, MNZO stock gained 0%.
MNZO is not paying dividends to its shareholders.
The last earnings report, released on Dec 31, 2015, exceeded the consensus estimates by 0.0056%. On average, the company has surpassed earnings expectations by 0.0011%, based on the last three reports.
Manzo Pharmaceuticals Inc. has completed 1 stock splits, with the recent split occurring on Sep 17, 2014.
The company's stock is traded on one exchange.
Manzo Pharmaceuticals Inc. (MNZO) FAQ
What is the stock price today?
The current price is $0.00.
On which exchange is it traded?
Manzo Pharmaceuticals Inc. is listed on EXPM.
What is its stock symbol?
The ticker symbol is MNZO.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 115.95K.
Has Manzo Pharmaceuticals Inc. ever had a stock split?
Manzo Pharmaceuticals Inc. had 1 splits and the recent split was on Sep 17, 2014.
Manzo Pharmaceuticals Inc. Profile
| Trading Companies & Distributors Industry | Industrials Sector | Kenneth Manzo CEO | EXPM Exchange | 56510D106 CUSIP |
| US Country | 12 Employees | - Last Dividend | 17 Sep 2014 Last Split | - IPO Date |
Overview
Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical company that has been active in the industry since it was initially incorporated in 1980. Originally known as Fortune Oil & Gas, Inc., it underwent a significant transformation in September 2014 when it changed its name to Manzo Pharmaceuticals, Inc. This marked a strategic pivot towards the pharmaceutical sector, focusing on the research, development, and testing of both patented and non-patented solutions and remedies. The company is headquartered in Milford, Pennsylvania, where it continues to pursue advancements in pharmaceuticals and health solutions tailored to specific medical needs.
Products and Services
- Lacto-Freedom: A patented probiotic designed to help people with lactose intolerance digest lactose-containing foods more effectively. This innovative product addresses the discomfort and digestive issues associated with lactose intolerance by aiding in the breakdown of lactose, thereby minimizing the occurrence of symptoms such as bloating, gas, and nausea. The development of Lacto-Freedom represents Manzo Pharmaceuticals' commitment to providing solutions that improve quality of life for individuals with dietary restrictions.
- Natural Remedy for Colic in Babies: Manzo Pharmaceuticals is also involved in developing a natural remedy aimed at alleviating colic symptoms in babies. Colic is a common condition that causes prolonged periods of crying or fussiness in infants, often linked to gastrointestinal discomfort. The company's dedication to creating a natural, safe solution for colic demonstrates its broader commitment to addressing health issues from infancy through adulthood, emphasizing the importance of gentle, effective remedies for sensitive populations.
Contact Information
Address: PO Box 107
Phone: 570-249-6000
Website: https://www.lactofreedom.com
